#Zepbound Injection

[recentupdates]

How does Zepbound Injection Work for Weight Loss? - Gainesville VA

Zepbound is unique from other weight-loss injections, such as Wegovy (semaglutide).It’s the first weight-loss medication to target both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.

- Schedule your consultation today!

Source URL:https://lifestylephysicians.com/zepbound-injections/

[petersmith07]

Zepbound Injection for Better Weight Control

Make Zepbound Injection your weight management solution. The new medication helps regulate appetite and encourages a nutritious diet, which aids slow, steady weight loss.

[foxyfillerss]

FDA approved Zepbound available

[totalcompoundingpharmacy]

SlimBlend: Targeted Weight Loss Injection

Ditch the Pounds, Embrace the Confidence! SlimBlend's Targeted Weight Loss Injection – Your Shortcut to a New You. Get Ready for the Transformation!

[mynameismckenziemae]

hey mckenzie, this isn’t the usual type of asks you get but I’m just wondering what are your thoughts on drugs like wegovy or ozrmpic as a nurse? i need to lose weight and my doctor talked to me about it.

Hey nonny!

So I don’t deal with those types of meds with the specialty I work in, but this is what I do know/have heard:

All of them (ozempic, mounjaro, wegovy, zepbound, etc.) are expensive (insurance covers them for type 2 diabetes, not weight loss) and they’re hard to get because they’re in high demand.

They can make you really nauseous/sick to your stomach…which sucks, especially if you have emetophobia.

They’re injections, so if you don’t do well with needles, it’s probably not for you.

Without lifestyle changes, weight gain is likely after stopping it. Though, I have heard it does help some peoples “relationship” with food.

My biggest worry is the possible long-term effects that haven’t been discovered yet.

I’m sorry, this probably isn’t very helpful, but I don’t want to persuade you one way or the other.

Losing weight is hard 😩 But, you’re not alone. I too need to lose some. Here’s to achieving our goals in 2025 😘

*Disclaimer: this isn’t medical advice, these are just my opinions. I could be wrong 🤷🏻‍♀️ Please talk to your doctor or a pharmacist further…they know a LOT more than I do.*

[mindblowingscience]

A new generation of obesity drugs often delivers dramatic weight loss, but many patients wonder what happens when they stop treatment. ​One study published Monday in the Journal of the American Medical Association provides an answer: much of the weight comes back, signaling patients may be locked into long term dependence on the drugs. ​The research was based on weekly injections of tirzepatide, the compound in Eli Lilly's new weight loss drug Zepbound that was approved by the United States last month.

Continue Reading.

[bihansthot]

Today in TMI with Sol, I get really bad nausea with my period, I usually skip them because of horrible migraines which induce the nausea and the subsequent vomiting right? Well Wegovy has other plans, for some reason it lessens the efficacy of your birth control so boom unexpected period. (Don’t worry non self insert Sol has her tubes tied so no worries about unexpected surprises!) I also increased my dose of the Wegovy which has increased my nausea, long story short I puked coffee in the kitchen sink because I couldn’t make it to the bathroom in time. Thankfully I have prescription meds for the nausea I just didn’t realize how bad it was until it was too late. By some miracle dinner stayed down though so small wins. I’m down 27 pounds (10 naturally 17 with the Wegovy in 3 months) though so who gives a doodle about some silly puking right? I’m fine really, just sharing in case someone is thinking of starting Wegovy and no one explains things like this like my doctor didn’t. In my doctor’s defense she knows I’m very intelligent and well informed medically so she probably assumed I had done proper research on weight loss meds before talking to her about it. Spoilers I didn’t, but there are a lot of wonderful folks who have gone through are going through their journeys on TikTok and I’ve learned a lot. It shouldn’t put you off from starting your journey if you want to just make sure you get a script for zofran/ondansetron too. The vomiting comes on very, very quickly with little to no warning just as a heads up so just be careful dosing up. Also try using your thigh if you have bad nausea using your stomach sometimes different injection sites can decrease side effects though supposedly you lose more weight if you can tolerate the abdominal injections. I just didn’t really think of my nausea doubling from my period but now I know, it totally does. Also if you are on Wegovy/Zepbound any of the others and don’t have your tubes tied and are sexually active please please please use condoms too unless you are trying for a child because Ozempic babies as it’s called are a very real thing. Even if you think you can’t have a baby because of your weight the more you lose the more your fertility returns so your birth control may not be enough due to the reduced efficacy, be safe loves.

[scientologisabethmoss]

anya weight talk diary entry 2

(trigger warning)

over the last year and a half, i've seen a number of tweets and articles critical of the use of GLP-1 drugs for weight loss that essentially boil down to the overly sentimental idea of "ozempic is an appetite suppressant, it reduces the very human desire for food (and alcohol, and nicotine, and other substances or activities that could be addictive), and doesn't that desire, that want, make us oh so human? isn't that what ~humanity~ is about????"

and i just can't stand it. i really can't. it's so disingenuous and precious to me.

in a few minutes, i'll go to my kitchen and inject myself with zepbound for the third time. i'm entering my third week with it, i'm on 2.5mg at this point, and it's been great! what a fucking RELIEF to not be thinking about food constantly! for me, at this dosage, the effect is subtle, but still noticeable and meaningful. i still ate a whole bacon cheeseburger, with fries and a chocolate milkshake, this afternoon, and i LOVED it. but the thing is that even though i ate that burger 5 hours ago, i'm not hungry for another meal yet! and i cannot overstate how much of a relief that is. there are whole swaths of my day where i simply do not think about food because i am not hungry, and it's as simple as that. but when i do get hungry, and i tuck into a delicious meal, i really and truly enjoy it, just like i always have.

at this low dose, i'd say that i'm only eating between 10-20% less per meal than what i was typically eating in a meal prior to going on this medicine. the real difference i've noticed is that i can go from lunch midday to dinner at 7pm with only an apple as a snack in between.

i just can't stand the idea that constantly battling with a hyperfixation that has become destructive to you in some capacity is the correct, human thing to do. not everything has to be such a fucking slog. sometimes it's okay to make things easier on yourself.

(my mom has been on a GLP-1 drug for at least the last 7 years for her type 2 diabetes, and she's not some ascetic freak of nature. jesus. she's lost about 70 pounds, very gradually over the years, and it's been great for her. and she still can chow down when she wants!)

(also i'm the same level of horny as i've always been, thank you very much. i'm jacking off just fine, and multiple times a week, just in case you were *concerned*.)

[cleverhottubmiracle]

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. Yet the interest in these miracle drugs has presented some challenges. Not only are insurance companies sometimes balking at paying for the medications, which can cost as much as $16,000 a year, but ongoing shortages have created opportunities for lower-priced copycats. It also remains unclear whether pharma companies can actually deliver on the promise of even better weight-loss drugs — part of the premise behind their high stock prices. Another unknown variable is Robert F. Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.What’s happening with the supply of GLP-1s?The two main GLP-1 obesity drugs currently on the market are Novo’s Wegovy and Lilly’s Zepbound, which are both taken as weekly injections. (Wegovy contains the same drug that’s in Ozempic, which is approved by the US Food and Drug Administration to treat diabetes, but at a slightly higher dose, while Zepbound contains the same medicine as Lilly’s diabetes drug Mounjaro.) The two companies have struggled to meet demand since introducing the drugs. So how have millions of Americans gotten the drugs, especially when insurance doesn’t always cover them? Through a legal provision that’s infuriated Lilly and Novo, which have been investing billions of dollars in manufacturing to increase supply. Whenever a drug is in shortage or otherwise not “commercially available,” the FDA allows compounders — a type of licensed pharmacy — to make and sell their own off-brand copycats. These compounded versions, available through telehealth companies such as Hims & Hers Health Inc. that widely advertise them on social media, cost a fraction of the brand-name versions and are generating as much as $1 billion a year for compounding pharmacies.Compounders have sued the FDA, which has flip-flopped on whether Lilly’s drugs Mounjaro and Zepbound are still in shortage; a ruling that they are would, in effect, prohibit compounders from making copies. In December, the FDA said the drugs were no longer in shortage — meaning compounders have 60 to 90 days to stop making copycats of Lilly’s drugs — but litigation is ongoing. As of Dec. 31, Novo’s drugs remain in shortage, according to the FDA.What’s happening with insurance coverage?Many patients can’t get or have lost coverage by insurers who refuse to cover the expensive drugs, leaving consumers to pay out of pocket or just buy the copycat versions, which are typically cheaper. About 44 percent of large employers cover the drugs for weight loss, but nearly all restrict coverage to those who meet certain narrow criteria, according to Mercer’s National Survey of Employer-Sponsored Health Plans.Medicare, the government health plan for Americans age 65 and over, does not cover drugs for weight loss. However, President Joe Biden’s administration recently proposed a rule that would require the US government to cover obesity drugs for millions of Americans on Medicare. The Trump administration will be able to finalise or block the proposed rule. It’s unclear where Trump stands on the issue. Kennedy, his pick to lead HHS, which oversees the FDA and the Centers for Medicare and Medicaid Services, has criticised the use of drugs for weight loss. In a September post on X, he argued that America should focus instead on “fixing our food system and addressing the obesity crisis at its root.” On the other hand, Trump’s close adviser Elon Musk has championed making GLP-1s “super low cost to the public” and claims to have taken such drugs himself. Which GLP-1 is most effective?Both obesity drugs on the market cause weight loss by mimicking an appetite-controlling gut hormone called GLP-1, which is released after eating and makes people feel full. Zepbound also targets a second related gut hormone called GIP, which helps lower blood sugar and may boost metabolism. Zepbound beat Wegovy in a head-to-head trial sponsored by Lilly. Of 751 patients with obesity, those on Zepbound lost 20.2 percent of their weight over 72 weeks, while those on Wegovy lost just 13.7 percent of their weight, according to the company’s announcement in early December. Both drugs have other benefits that extend beyond weight loss. Wegovy is the only GLP-1 drug proven to prevent heart attacks and other cardiovascular events in people with heart disease and obesity. In December, Zepbound also became the first drug approved to treat sleep apnea.Could future drugs improve upon these results?Potential profits have lured a growing number of drugmakers to try to develop their own weight-loss treatments. Meanwhile, frontrunners Lilly and Novo are racing to develop treatments that outperform their current blockbusters before their patents run out. However, it’s unclear how much drug companies will be able to improve upon Zepbound’s efficacy, if at all. Novo is testing a next-generation drug called CagriSema that company executives have repeatedly suggested could produce even more weight loss than Zepbound. CagriSema combines a GLP-1 with another compound, called cagrilintide, which mimics a hormone called amylin.Both the old and the new medicines suppress the appetite, though drugmakers describe the effects of amylin-imitating drugs as a gentler experience than a GLP-1 drug, helping people stay satisfied for longer instead of wiping away their drive to eat. But the first big study of CagriSema, which was published in December, found that the drug produced about 20.4 percent weight loss over 68 weeks, roughly equivalent to Zepbound. Novo shares plummeted. The company is continuing to study the medicine in other trials, including a head-to-head trial versus Zepbound.Another promising next-generation drug is Lilly’s retatrutide. It imitates three hormones: GLP-1; GIP; and glucagon, which helps control blood sugar levels. The drug helped people lose up to about 24 percent of their body weight in a 2023 mid-stage study and is now in final stage trials, with results due in 2026.How far off are pill versions of GLP-1 drugs?Several companies are working on obesity pills that could produce substantial weight loss without the need for weekly injections. But so far, many efforts to come up with obesity pills have encountered setbacks. Pfizer Inc. has struggled to develop a pill, with one prospect failing entirely in June 2023. Trials of a twice-daily compound were discontinued later that year because of side effects. The company is now working on a new once-a-day formulation. Meanwhile, shares of Roche dropped in September after its experimental pill carried severe side effects in a preliminary study. Numerous other companies remain in early stages of testing obesity pills, including Merck & Co., which licensed an experimental obesity pill that was in preclinical testing in December.That leaves Lilly as having one of the most advanced obesity pills in testing. Its pill, orforglipron, is in late-stage trials, with results due in 2025. In mid-stage trials published in 2023, participants on the drug lost as much as 14.7 percent of their body weight over 36 weeks.What about drugs that don’t need to be injected as frequently?Drugmakers are also trying to come up with drugs that are just as effective as current shots, but require fewer injections. That’s gone slowly, too. Amgen Inc. shares fell in late November after its experimental drug, dubbed MariTide, failed to significantly outperform rivals in a mid-stage trial. The drug is taken every month, and Amgen is testing whether patients can wait even longer between shots. However, as many as 40 percent of patients experienced vomiting, particularly in the days immediately after the first dose. Why isn’t progress faster?In general, drug development is a slow process. It’s usually marked by incremental improvements or outright disappointments, and only occasionally by breakthroughs. Obesity drug development was a graveyard for drugmakers for many years. Wegovy and Zepbound, the first-ever highly effective treatments, were major advances. It’s not a surprise that attempts to improve on these drugs may fall short of investor expectations.By Ike Swetlitz, Madison Muller and Robert Langreth Source link

[norajworld]

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. Yet the interest in these miracle drugs has presented some challenges. Not only are insurance companies sometimes balking at paying for the medications, which can cost as much as $16,000 a year, but ongoing shortages have created opportunities for lower-priced copycats. It also remains unclear whether pharma companies can actually deliver on the promise of even better weight-loss drugs — part of the premise behind their high stock prices. Another unknown variable is Robert F. Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.What’s happening with the supply of GLP-1s?The two main GLP-1 obesity drugs currently on the market are Novo’s Wegovy and Lilly’s Zepbound, which are both taken as weekly injections. (Wegovy contains the same drug that’s in Ozempic, which is approved by the US Food and Drug Administration to treat diabetes, but at a slightly higher dose, while Zepbound contains the same medicine as Lilly’s diabetes drug Mounjaro.) The two companies have struggled to meet demand since introducing the drugs. So how have millions of Americans gotten the drugs, especially when insurance doesn’t always cover them? Through a legal provision that’s infuriated Lilly and Novo, which have been investing billions of dollars in manufacturing to increase supply. Whenever a drug is in shortage or otherwise not “commercially available,” the FDA allows compounders — a type of licensed pharmacy — to make and sell their own off-brand copycats. These compounded versions, available through telehealth companies such as Hims & Hers Health Inc. that widely advertise them on social media, cost a fraction of the brand-name versions and are generating as much as $1 billion a year for compounding pharmacies.Compounders have sued the FDA, which has flip-flopped on whether Lilly’s drugs Mounjaro and Zepbound are still in shortage; a ruling that they are would, in effect, prohibit compounders from making copies. In December, the FDA said the drugs were no longer in shortage — meaning compounders have 60 to 90 days to stop making copycats of Lilly’s drugs — but litigation is ongoing. As of Dec. 31, Novo’s drugs remain in shortage, according to the FDA.What’s happening with insurance coverage?Many patients can’t get or have lost coverage by insurers who refuse to cover the expensive drugs, leaving consumers to pay out of pocket or just buy the copycat versions, which are typically cheaper. About 44 percent of large employers cover the drugs for weight loss, but nearly all restrict coverage to those who meet certain narrow criteria, according to Mercer’s National Survey of Employer-Sponsored Health Plans.Medicare, the government health plan for Americans age 65 and over, does not cover drugs for weight loss. However, President Joe Biden’s administration recently proposed a rule that would require the US government to cover obesity drugs for millions of Americans on Medicare. The Trump administration will be able to finalise or block the proposed rule. It’s unclear where Trump stands on the issue. Kennedy, his pick to lead HHS, which oversees the FDA and the Centers for Medicare and Medicaid Services, has criticised the use of drugs for weight loss. In a September post on X, he argued that America should focus instead on “fixing our food system and addressing the obesity crisis at its root.” On the other hand, Trump’s close adviser Elon Musk has championed making GLP-1s “super low cost to the public” and claims to have taken such drugs himself. Which GLP-1 is most effective?Both obesity drugs on the market cause weight loss by mimicking an appetite-controlling gut hormone called GLP-1, which is released after eating and makes people feel full. Zepbound also targets a second related gut hormone called GIP, which helps lower blood sugar and may boost metabolism. Zepbound beat Wegovy in a head-to-head trial sponsored by Lilly. Of 751 patients with obesity, those on Zepbound lost 20.2 percent of their weight over 72 weeks, while those on Wegovy lost just 13.7 percent of their weight, according to the company’s announcement in early December. Both drugs have other benefits that extend beyond weight loss. Wegovy is the only GLP-1 drug proven to prevent heart attacks and other cardiovascular events in people with heart disease and obesity. In December, Zepbound also became the first drug approved to treat sleep apnea.Could future drugs improve upon these results?Potential profits have lured a growing number of drugmakers to try to develop their own weight-loss treatments. Meanwhile, frontrunners Lilly and Novo are racing to develop treatments that outperform their current blockbusters before their patents run out. However, it’s unclear how much drug companies will be able to improve upon Zepbound’s efficacy, if at all. Novo is testing a next-generation drug called CagriSema that company executives have repeatedly suggested could produce even more weight loss than Zepbound. CagriSema combines a GLP-1 with another compound, called cagrilintide, which mimics a hormone called amylin.Both the old and the new medicines suppress the appetite, though drugmakers describe the effects of amylin-imitating drugs as a gentler experience than a GLP-1 drug, helping people stay satisfied for longer instead of wiping away their drive to eat. But the first big study of CagriSema, which was published in December, found that the drug produced about 20.4 percent weight loss over 68 weeks, roughly equivalent to Zepbound. Novo shares plummeted. The company is continuing to study the medicine in other trials, including a head-to-head trial versus Zepbound.Another promising next-generation drug is Lilly’s retatrutide. It imitates three hormones: GLP-1; GIP; and glucagon, which helps control blood sugar levels. The drug helped people lose up to about 24 percent of their body weight in a 2023 mid-stage study and is now in final stage trials, with results due in 2026.How far off are pill versions of GLP-1 drugs?Several companies are working on obesity pills that could produce substantial weight loss without the need for weekly injections. But so far, many efforts to come up with obesity pills have encountered setbacks. Pfizer Inc. has struggled to develop a pill, with one prospect failing entirely in June 2023. Trials of a twice-daily compound were discontinued later that year because of side effects. The company is now working on a new once-a-day formulation. Meanwhile, shares of Roche dropped in September after its experimental pill carried severe side effects in a preliminary study. Numerous other companies remain in early stages of testing obesity pills, including Merck & Co., which licensed an experimental obesity pill that was in preclinical testing in December.That leaves Lilly as having one of the most advanced obesity pills in testing. Its pill, orforglipron, is in late-stage trials, with results due in 2025. In mid-stage trials published in 2023, participants on the drug lost as much as 14.7 percent of their body weight over 36 weeks.What about drugs that don’t need to be injected as frequently?Drugmakers are also trying to come up with drugs that are just as effective as current shots, but require fewer injections. That’s gone slowly, too. Amgen Inc. shares fell in late November after its experimental drug, dubbed MariTide, failed to significantly outperform rivals in a mid-stage trial. The drug is taken every month, and Amgen is testing whether patients can wait even longer between shots. However, as many as 40 percent of patients experienced vomiting, particularly in the days immediately after the first dose. Why isn’t progress faster?In general, drug development is a slow process. It’s usually marked by incremental improvements or outright disappointments, and only occasionally by breakthroughs. Obesity drug development was a graveyard for drugmakers for many years. Wegovy and Zepbound, the first-ever highly effective treatments, were major advances. It’s not a surprise that attempts to improve on these drugs may fall short of investor expectations.By Ike Swetlitz, Madison Muller and Robert Langreth Source link

[ellajme0]

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. Yet the interest in these miracle drugs has presented some challenges. Not only are insurance companies sometimes balking at paying for the medications, which can cost as much as $16,000 a year, but ongoing shortages have created opportunities for lower-priced copycats. It also remains unclear whether pharma companies can actually deliver on the promise of even better weight-loss drugs — part of the premise behind their high stock prices. Another unknown variable is Robert F. Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.What’s happening with the supply of GLP-1s?The two main GLP-1 obesity drugs currently on the market are Novo’s Wegovy and Lilly’s Zepbound, which are both taken as weekly injections. (Wegovy contains the same drug that’s in Ozempic, which is approved by the US Food and Drug Administration to treat diabetes, but at a slightly higher dose, while Zepbound contains the same medicine as Lilly’s diabetes drug Mounjaro.) The two companies have struggled to meet demand since introducing the drugs. So how have millions of Americans gotten the drugs, especially when insurance doesn’t always cover them? Through a legal provision that’s infuriated Lilly and Novo, which have been investing billions of dollars in manufacturing to increase supply. Whenever a drug is in shortage or otherwise not “commercially available,” the FDA allows compounders — a type of licensed pharmacy — to make and sell their own off-brand copycats. These compounded versions, available through telehealth companies such as Hims & Hers Health Inc. that widely advertise them on social media, cost a fraction of the brand-name versions and are generating as much as $1 billion a year for compounding pharmacies.Compounders have sued the FDA, which has flip-flopped on whether Lilly’s drugs Mounjaro and Zepbound are still in shortage; a ruling that they are would, in effect, prohibit compounders from making copies. In December, the FDA said the drugs were no longer in shortage ��� meaning compounders have 60 to 90 days to stop making copycats of Lilly’s drugs — but litigation is ongoing. As of Dec. 31, Novo’s drugs remain in shortage, according to the FDA.What’s happening with insurance coverage?Many patients can’t get or have lost coverage by insurers who refuse to cover the expensive drugs, leaving consumers to pay out of pocket or just buy the copycat versions, which are typically cheaper. About 44 percent of large employers cover the drugs for weight loss, but nearly all restrict coverage to those who meet certain narrow criteria, according to Mercer’s National Survey of Employer-Sponsored Health Plans.Medicare, the government health plan for Americans age 65 and over, does not cover drugs for weight loss. However, President Joe Biden’s administration recently proposed a rule that would require the US government to cover obesity drugs for millions of Americans on Medicare. The Trump administration will be able to finalise or block the proposed rule. It’s unclear where Trump stands on the issue. Kennedy, his pick to lead HHS, which oversees the FDA and the Centers for Medicare and Medicaid Services, has criticised the use of drugs for weight loss. In a September post on X, he argued that America should focus instead on “fixing our food system and addressing the obesity crisis at its root.” On the other hand, Trump’s close adviser Elon Musk has championed making GLP-1s “super low cost to the public” and claims to have taken such drugs himself. Which GLP-1 is most effective?Both obesity drugs on the market cause weight loss by mimicking an appetite-controlling gut hormone called GLP-1, which is released after eating and makes people feel full. Zepbound also targets a second related gut hormone called GIP, which helps lower blood sugar and may boost metabolism. Zepbound beat Wegovy in a head-to-head trial sponsored by Lilly. Of 751 patients with obesity, those on Zepbound lost 20.2 percent of their weight over 72 weeks, while those on Wegovy lost just 13.7 percent of their weight, according to the company’s announcement in early December. Both drugs have other benefits that extend beyond weight loss. Wegovy is the only GLP-1 drug proven to prevent heart attacks and other cardiovascular events in people with heart disease and obesity. In December, Zepbound also became the first drug approved to treat sleep apnea.Could future drugs improve upon these results?Potential profits have lured a growing number of drugmakers to try to develop their own weight-loss treatments. Meanwhile, frontrunners Lilly and Novo are racing to develop treatments that outperform their current blockbusters before their patents run out. However, it’s unclear how much drug companies will be able to improve upon Zepbound’s efficacy, if at all. Novo is testing a next-generation drug called CagriSema that company executives have repeatedly suggested could produce even more weight loss than Zepbound. CagriSema combines a GLP-1 with another compound, called cagrilintide, which mimics a hormone called amylin.Both the old and the new medicines suppress the appetite, though drugmakers describe the effects of amylin-imitating drugs as a gentler experience than a GLP-1 drug, helping people stay satisfied for longer instead of wiping away their drive to eat. But the first big study of CagriSema, which was published in December, found that the drug produced about 20.4 percent weight loss over 68 weeks, roughly equivalent to Zepbound. Novo shares plummeted. The company is continuing to study the medicine in other trials, including a head-to-head trial versus Zepbound.Another promising next-generation drug is Lilly’s retatrutide. It imitates three hormones: GLP-1; GIP; and glucagon, which helps control blood sugar levels. The drug helped people lose up to about 24 percent of their body weight in a 2023 mid-stage study and is now in final stage trials, with results due in 2026.How far off are pill versions of GLP-1 drugs?Several companies are working on obesity pills that could produce substantial weight loss without the need for weekly injections. But so far, many efforts to come up with obesity pills have encountered setbacks. Pfizer Inc. has struggled to develop a pill, with one prospect failing entirely in June 2023. Trials of a twice-daily compound were discontinued later that year because of side effects. The company is now working on a new once-a-day formulation. Meanwhile, shares of Roche dropped in September after its experimental pill carried severe side effects in a preliminary study. Numerous other companies remain in early stages of testing obesity pills, including Merck & Co., which licensed an experimental obesity pill that was in preclinical testing in December.That leaves Lilly as having one of the most advanced obesity pills in testing. Its pill, orforglipron, is in late-stage trials, with results due in 2025. In mid-stage trials published in 2023, participants on the drug lost as much as 14.7 percent of their body weight over 36 weeks.What about drugs that don’t need to be injected as frequently?Drugmakers are also trying to come up with drugs that are just as effective as current shots, but require fewer injections. That’s gone slowly, too. Amgen Inc. shares fell in late November after its experimental drug, dubbed MariTide, failed to significantly outperform rivals in a mid-stage trial. The drug is taken every month, and Amgen is testing whether patients can wait even longer between shots. However, as many as 40 percent of patients experienced vomiting, particularly in the days immediately after the first dose. Why isn’t progress faster?In general, drug development is a slow process. It’s usually marked by incremental improvements or outright disappointments, and only occasionally by breakthroughs. Obesity drug development was a graveyard for drugmakers for many years. Wegovy and Zepbound, the first-ever highly effective treatments, were major advances. It’s not a surprise that attempts to improve on these drugs may fall short of investor expectations.By Ike Swetlitz, Madison Muller and Robert Langreth Source link

[recentupdates]

How does Zepbound (tirzepatide) Injection Work? Warrenton

Zepbound (tirzepatide) Injection mimics the action of two natural hormones, GLP-1 and GIP. These hormones help regulate blood sugar, appetite, and weight.

When injected, Zepbound binds to specific receptors in the body, leading to: 1. Reduced blood sugar: By stimulating insulin production and decreasing glucagon secretion. 2. Decreased appetite: By making you feel fuller for longer. 3. Weight loss: By helping you eat less and burn more calories.

Source Page: https://lifestylephysicians.com/zepbound-injections/

Contact Page Form

[petersmith07]

Rybelsus Oral Tablet: Easy and Efficient Management of Diabetes

Rybelsus Oral Tablet is the first oral GLP-1 receptor agonist for Type 2 diabetes; say goodbye to daily injections. You can find out more about its effectiveness, ease of use, and seamless integration into your life to provide better overall health and blood sugar control.

[totalcompoundingpharmacy]

Injecting Progress: A Deep Dive into Weight Loss Injection Therapy

Dive into the transformative world of Weight Loss Injection Therapy! 🌟💉 Explore the science behind this innovative approach and discover how it's reshaping wellness journeys. Ready to inject progress into your weight loss goals? Join the conversation now!

[chilimili212]

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. Yet the interest in these miracle drugs has presented some challenges. Not only are insurance companies sometimes balking at paying for the medications, which can cost as much as $16,000 a year, but ongoing shortages have created opportunities for lower-priced copycats. It also remains unclear whether pharma companies can actually deliver on the promise of even better weight-loss drugs — part of the premise behind their high stock prices. Another unknown variable is Robert F. Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.What’s happening with the supply of GLP-1s?The two main GLP-1 obesity drugs currently on the market are Novo’s Wegovy and Lilly’s Zepbound, which are both taken as weekly injections. (Wegovy contains the same drug that’s in Ozempic, which is approved by the US Food and Drug Administration to treat diabetes, but at a slightly higher dose, while Zepbound contains the same medicine as Lilly’s diabetes drug Mounjaro.) The two companies have struggled to meet demand since introducing the drugs. So how have millions of Americans gotten the drugs, especially when insurance doesn’t always cover them? Through a legal provision that’s infuriated Lilly and Novo, which have been investing billions of dollars in manufacturing to increase supply. Whenever a drug is in shortage or otherwise not “commercially available,” the FDA allows compounders — a type of licensed pharmacy — to make and sell their own off-brand copycats. These compounded versions, available through telehealth companies such as Hims & Hers Health Inc. that widely advertise them on social media, cost a fraction of the brand-name versions and are generating as much as $1 billion a year for compounding pharmacies.Compounders have sued the FDA, which has flip-flopped on whether Lilly’s drugs Mounjaro and Zepbound are still in shortage; a ruling that they are would, in effect, prohibit compounders from making copies. In December, the FDA said the drugs were no longer in shortage — meaning compounders have 60 to 90 days to stop making copycats of Lilly’s drugs — but litigation is ongoing. As of Dec. 31, Novo’s drugs remain in shortage, according to the FDA.What’s happening with insurance coverage?Many patients can’t get or have lost coverage by insurers who refuse to cover the expensive drugs, leaving consumers to pay out of pocket or just buy the copycat versions, which are typically cheaper. About 44 percent of large employers cover the drugs for weight loss, but nearly all restrict coverage to those who meet certain narrow criteria, according to Mercer’s National Survey of Employer-Sponsored Health Plans.Medicare, the government health plan for Americans age 65 and over, does not cover drugs for weight loss. However, President Joe Biden’s administration recently proposed a rule that would require the US government to cover obesity drugs for millions of Americans on Medicare. The Trump administration will be able to finalise or block the proposed rule. It’s unclear where Trump stands on the issue. Kennedy, his pick to lead HHS, which oversees the FDA and the Centers for Medicare and Medicaid Services, has criticised the use of drugs for weight loss. In a September post on X, he argued that America should focus instead on “fixing our food system and addressing the obesity crisis at its root.” On the other hand, Trump’s close adviser Elon Musk has championed making GLP-1s “super low cost to the public” and claims to have taken such drugs himself. Which GLP-1 is most effective?Both obesity drugs on the market cause weight loss by mimicking an appetite-controlling gut hormone called GLP-1, which is released after eating and makes people feel full. Zepbound also targets a second related gut hormone called GIP, which helps lower blood sugar and may boost metabolism. Zepbound beat Wegovy in a head-to-head trial sponsored by Lilly. Of 751 patients with obesity, those on Zepbound lost 20.2 percent of their weight over 72 weeks, while those on Wegovy lost just 13.7 percent of their weight, according to the company’s announcement in early December. Both drugs have other benefits that extend beyond weight loss. Wegovy is the only GLP-1 drug proven to prevent heart attacks and other cardiovascular events in people with heart disease and obesity. In December, Zepbound also became the first drug approved to treat sleep apnea.Could future drugs improve upon these results?Potential profits have lured a growing number of drugmakers to try to develop their own weight-loss treatments. Meanwhile, frontrunners Lilly and Novo are racing to develop treatments that outperform their current blockbusters before their patents run out. However, it’s unclear how much drug companies will be able to improve upon Zepbound’s efficacy, if at all. Novo is testing a next-generation drug called CagriSema that company executives have repeatedly suggested could produce even more weight loss than Zepbound. CagriSema combines a GLP-1 with another compound, called cagrilintide, which mimics a hormone called amylin.Both the old and the new medicines suppress the appetite, though drugmakers describe the effects of amylin-imitating drugs as a gentler experience than a GLP-1 drug, helping people stay satisfied for longer instead of wiping away their drive to eat. But the first big study of CagriSema, which was published in December, found that the drug produced about 20.4 percent weight loss over 68 weeks, roughly equivalent to Zepbound. Novo shares plummeted. The company is continuing to study the medicine in other trials, including a head-to-head trial versus Zepbound.Another promising next-generation drug is Lilly’s retatrutide. It imitates three hormones: GLP-1; GIP; and glucagon, which helps control blood sugar levels. The drug helped people lose up to about 24 percent of their body weight in a 2023 mid-stage study and is now in final stage trials, with results due in 2026.How far off are pill versions of GLP-1 drugs?Several companies are working on obesity pills that could produce substantial weight loss without the need for weekly injections. But so far, many efforts to come up with obesity pills have encountered setbacks. Pfizer Inc. has struggled to develop a pill, with one prospect failing entirely in June 2023. Trials of a twice-daily compound were discontinued later that year because of side effects. The company is now working on a new once-a-day formulation. Meanwhile, shares of Roche dropped in September after its experimental pill carried severe side effects in a preliminary study. Numerous other companies remain in early stages of testing obesity pills, including Merck & Co., which licensed an experimental obesity pill that was in preclinical testing in December.That leaves Lilly as having one of the most advanced obesity pills in testing. Its pill, orforglipron, is in late-stage trials, with results due in 2025. In mid-stage trials published in 2023, participants on the drug lost as much as 14.7 percent of their body weight over 36 weeks.What about drugs that don’t need to be injected as frequently?Drugmakers are also trying to come up with drugs that are just as effective as current shots, but require fewer injections. That’s gone slowly, too. Amgen Inc. shares fell in late November after its experimental drug, dubbed MariTide, failed to significantly outperform rivals in a mid-stage trial. The drug is taken every month, and Amgen is testing whether patients can wait even longer between shots. However, as many as 40 percent of patients experienced vomiting, particularly in the days immediately after the first dose. Why isn’t progress faster?In general, drug development is a slow process. It’s usually marked by incremental improvements or outright disappointments, and only occasionally by breakthroughs. Obesity drug development was a graveyard for drugmakers for many years. Wegovy and Zepbound, the first-ever highly effective treatments, were major advances. It’s not a surprise that attempts to improve on these drugs may fall short of investor expectations.By Ike Swetlitz, Madison Muller and Robert Langreth Source link

[oliviajoyice21]

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. Yet the interest in these miracle drugs has presented some challenges. Not only are insurance companies sometimes balking at paying for the medications, which can cost as much as $16,000 a year, but ongoing shortages have created opportunities for lower-priced copycats. It also remains unclear whether pharma companies can actually deliver on the promise of even better weight-loss drugs — part of the premise behind their high stock prices. Another unknown variable is Robert F. Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.What’s happening with the supply of GLP-1s?The two main GLP-1 obesity drugs currently on the market are Novo’s Wegovy and Lilly’s Zepbound, which are both taken as weekly injections. (Wegovy contains the same drug that’s in Ozempic, which is approved by the US Food and Drug Administration to treat diabetes, but at a slightly higher dose, while Zepbound contains the same medicine as Lilly’s diabetes drug Mounjaro.) The two companies have struggled to meet demand since introducing the drugs. So how have millions of Americans gotten the drugs, especially when insurance doesn’t always cover them? Through a legal provision that’s infuriated Lilly and Novo, which have been investing billions of dollars in manufacturing to increase supply. Whenever a drug is in shortage or otherwise not “commercially available,” the FDA allows compounders — a type of licensed pharmacy — to make and sell their own off-brand copycats. These compounded versions, available through telehealth companies such as Hims & Hers Health Inc. that widely advertise them on social media, cost a fraction of the brand-name versions and are generating as much as $1 billion a year for compounding pharmacies.Compounders have sued the FDA, which has flip-flopped on whether Lilly’s drugs Mounjaro and Zepbound are still in shortage; a ruling that they are would, in effect, prohibit compounders from making copies. In December, the FDA said the drugs were no longer in shortage — meaning compounders have 60 to 90 days to stop making copycats of Lilly’s drugs — but litigation is ongoing. As of Dec. 31, Novo’s drugs remain in shortage, according to the FDA.What’s happening with insurance coverage?Many patients can’t get or have lost coverage by insurers who refuse to cover the expensive drugs, leaving consumers to pay out of pocket or just buy the copycat versions, which are typically cheaper. About 44 percent of large employers cover the drugs for weight loss, but nearly all restrict coverage to those who meet certain narrow criteria, according to Mercer’s National Survey of Employer-Sponsored Health Plans.Medicare, the government health plan for Americans age 65 and over, does not cover drugs for weight loss. However, President Joe Biden’s administration recently proposed a rule that would require the US government to cover obesity drugs for millions of Americans on Medicare. The Trump administration will be able to finalise or block the proposed rule. It’s unclear where Trump stands on the issue. Kennedy, his pick to lead HHS, which oversees the FDA and the Centers for Medicare and Medicaid Services, has criticised the use of drugs for weight loss. In a September post on X, he argued that America should focus instead on “fixing our food system and addressing the obesity crisis at its root.” On the other hand, Trump’s close adviser Elon Musk has championed making GLP-1s “super low cost to the public” and claims to have taken such drugs himself. Which GLP-1 is most effective?Both obesity drugs on the market cause weight loss by mimicking an appetite-controlling gut hormone called GLP-1, which is released after eating and makes people feel full. Zepbound also targets a second related gut hormone called GIP, which helps lower blood sugar and may boost metabolism. Zepbound beat Wegovy in a head-to-head trial sponsored by Lilly. Of 751 patients with obesity, those on Zepbound lost 20.2 percent of their weight over 72 weeks, while those on Wegovy lost just 13.7 percent of their weight, according to the company’s announcement in early December. Both drugs have other benefits that extend beyond weight loss. Wegovy is the only GLP-1 drug proven to prevent heart attacks and other cardiovascular events in people with heart disease and obesity. In December, Zepbound also became the first drug approved to treat sleep apnea.Could future drugs improve upon these results?Potential profits have lured a growing number of drugmakers to try to develop their own weight-loss treatments. Meanwhile, frontrunners Lilly and Novo are racing to develop treatments that outperform their current blockbusters before their patents run out. However, it’s unclear how much drug companies will be able to improve upon Zepbound’s efficacy, if at all. Novo is testing a next-generation drug called CagriSema that company executives have repeatedly suggested could produce even more weight loss than Zepbound. CagriSema combines a GLP-1 with another compound, called cagrilintide, which mimics a hormone called amylin.Both the old and the new medicines suppress the appetite, though drugmakers describe the effects of amylin-imitating drugs as a gentler experience than a GLP-1 drug, helping people stay satisfied for longer instead of wiping away their drive to eat. But the first big study of CagriSema, which was published in December, found that the drug produced about 20.4 percent weight loss over 68 weeks, roughly equivalent to Zepbound. Novo shares plummeted. The company is continuing to study the medicine in other trials, including a head-to-head trial versus Zepbound.Another promising next-generation drug is Lilly’s retatrutide. It imitates three hormones: GLP-1; GIP; and glucagon, which helps control blood sugar levels. The drug helped people lose up to about 24 percent of their body weight in a 2023 mid-stage study and is now in final stage trials, with results due in 2026.How far off are pill versions of GLP-1 drugs?Several companies are working on obesity pills that could produce substantial weight loss without the need for weekly injections. But so far, many efforts to come up with obesity pills have encountered setbacks. Pfizer Inc. has struggled to develop a pill, with one prospect failing entirely in June 2023. Trials of a twice-daily compound were discontinued later that year because of side effects. The company is now working on a new once-a-day formulation. Meanwhile, shares of Roche dropped in September after its experimental pill carried severe side effects in a preliminary study. Numerous other companies remain in early stages of testing obesity pills, including Merck & Co., which licensed an experimental obesity pill that was in preclinical testing in December.That leaves Lilly as having one of the most advanced obesity pills in testing. Its pill, orforglipron, is in late-stage trials, with results due in 2025. In mid-stage trials published in 2023, participants on the drug lost as much as 14.7 percent of their body weight over 36 weeks.What about drugs that don’t need to be injected as frequently?Drugmakers are also trying to come up with drugs that are just as effective as current shots, but require fewer injections. That’s gone slowly, too. Amgen Inc. shares fell in late November after its experimental drug, dubbed MariTide, failed to significantly outperform rivals in a mid-stage trial. The drug is taken every month, and Amgen is testing whether patients can wait even longer between shots. However, as many as 40 percent of patients experienced vomiting, particularly in the days immediately after the first dose. Why isn’t progress faster?In general, drug development is a slow process. It’s usually marked by incremental improvements or outright disappointments, and only occasionally by breakthroughs. Obesity drug development was a graveyard for drugmakers for many years. Wegovy and Zepbound, the first-ever highly effective treatments, were major advances. It’s not a surprise that attempts to improve on these drugs may fall short of investor expectations.By Ike Swetlitz, Madison Muller and Robert Langreth Source link